NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Shu Chen
Auburn University - Auburn / United States
Agriculture & Forestry / Plant Science
AD Scientific Index ID: 858374
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Shu Chen's MOST POPULAR ARTICLES
1-)
MONARCH 3: abemaciclib as initial therapy for advanced breast cancerMP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ...Journal of Clinical Oncology 35 (32), 3638-3646, 201710762017
2-)
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk …M Van Der Velde, K Matsushita, J Coresh, BC Astor, M Woodward, ...Kidney international 79 (12), 1341-1352, 20119442011
3-)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialM Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...The lancet oncology 18 (12), 1688-1700, 20175172017
4-)
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trialC Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ...Journal of Clinical Oncology 38 (27), 3138-3149, 20205062020
5-)
Interleukin‐23: as a drug target for autoimmune inflammatory diseasesC Tang, S Chen, H Qian, W HuangImmunology 135 (2), 112-124, 20124242012
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept